二甲双胍与2型糖尿病患者肺结核感染风险的倾向性评分匹配分析

doi:10.19871/j.cnki.xfcrbzz.2021.03.008

摘要/Abstract

摘要： 目的探讨二甲双胍与2型糖尿病（T2DM）患者肺结核（TB）感染风险的相关性,为T2DM患者治疗方式选择提供参考。方法选择2019年1月至2019年12月恩施州民族医院感染性疾病科就诊的T2DM患者179例,其中确诊TB患者58例,未患有TB患者121例。收集患者二甲双胍使用情况、临床资料及实验室检查资料。通过倾向性评分匹配两组患者,然后通过Logistic回归分析二甲双胍使用率与匹配后T2MD患者TB发生的相关性。结果 TB组患者二甲双胍使用率显著低于非TB组,而TB接触史及血清肌酐均显著高于非TB组（χ²=9.375、4.529,t=2.112,P=0.002、0.033、0.036）。二甲双胍使用（OR=0.368,95%CI=0.167~0.811）是影响TB发生的独立保护因素,而TB接触史（OR=3.007,95%CI=1.026~8.815）是影响TB发生的危险因素（P=0.013、0.045）。结论 T2DM患者长期服用二甲双胍可以降低TB发生的风险,可以考虑针对高TB风险的T2DM患者采用联合二甲双胍的治疗方案,从而降低患者TB发生的风险。

关键词: 2型糖尿病, 肺结核, 二甲双胍, 倾向性评分匹配

Abstract: Objective To investigate the correlation between metformin and the risk of pulmonary tuberculosis (TB) infection in patients with type 2 diabetes (T2DM) and provide reference for the treatment of T2DM patients. Methods 179 patients with T2DM who were treated in the Department of Infectious Diseases of Enshi Minority Hospital from January 2019 to December 2019 were selected, of which 58 patients were diagnosed with TB and 121 patients did not suffer from TB. Collect the patient's use of metformin, clinical data and laboratory examination data. The two groups of patients were matched by propensity score, and then the correlation between metformin use rate and the occurrence of TB in T2MD patients after matching was analyzed by Logistic regression. Results After the propensity score matching, the use rate of metformin in the TB group was significantly lower than that in the non-TB group, and the TB exposure history and Cr were significantly higher than those in the non-TB group（χ²=9.375、4.529,t=2.112,P=0.002、0.033、0.036）. Metformin use (OR=0.368, 95% CI= 0.167-0.811) is an independent protective factor that affects the occurrence of TB, and the history of TB exposure (OR=3.007, 95% CI=1.026-8.815) is a risk factor that affects the occurrence of TB （P=0.013、0.045）. Conclusion Long-term use of metformin in T2DM patients can reduce the risk of TB. Consider the combination of metformin treatment for T2DM patients with high TB risk, thereby reducing the risk of TB.

Key words: Type Ⅱ diabetes, Tuberculosis, Metformin, Propensity score matching

谭运彩, 袁媛, 杨双喜, 杨雪. 二甲双胍与2型糖尿病患者肺结核感染风险的倾向性评分匹配分析[J]. 新发传染病电子杂志, 2021, 6(3): 202-205.

Tan Yuncai, Yuan Yuan, Yang Shuangxi, Yang Xue. Matching analysis of propensity scores for metformin and tuberculosis infection risk in T2DM patient[J]. Electronic Journal of Emerging Infectious Diseases, 2021, 6(3): 202-205.

参考文献

[1] MASUPE TK, NDAYI K, TSOLEKILE L, et al.Redefining diabetes and the concept of self-management from a patient's perspective: implications for disease risk factor management[J]. Health Educ Res, 2018, 33(1):40-54.
[2] WANG X, MA A, HAN X, et al.T Cell Profile was Altered in Pulmonary Tuberculosis Patients with Type 2 Diabetes[J]. Med Sci Monit, 2018, 24(1):636-642.
[3] 罗一婷,翁榕星,周芳,等.2019WHO全球结核报告:全球与中国关键数据分析[J/CD].新发传染病电子杂志, 2020, 5(1):47-50.
[4] 陈永, 管剑龙 .二甲双胍与调节性T细胞/Th17细胞平衡[J].细胞与分子免疫学杂志,2016,32(12):1723-1726.
[5] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志, 2018, 10(1):4-67.
[6] 中华人民共和国国家卫生和计划生育委员会. 肺结核诊断标准(WS 288—2017)[J/CD]. 新发传染病电子杂志, 2018, 3(1):65-67.
[7] KUBIAK RW, SARKAR S, HORSBURGH CR, et al.Interaction of nutritional status and diabetes on active and latent tuberculosis: a cross-sectional analysis[J]. BMC Infect Dis, 2019,19(1):627.
[8] PAVLOVI JM, PAVLOVIC AD, BULAJI MV, et al.Prevalence of diabetes mellitus (DM) in tuberculosis (TB) patients: clinical and radiologic features in the TB-DM association based on a five-year hospital study[J]. Infez Med, 2018, 26(1):22-27.
[9] 王淑霞, 杜亚东, 马艳, 等.二甲双胍对复治肺结核并发糖尿病患者的疗效初探[J].中国防痨杂志, 2017, 39(5):476-481.
[10] 李青, 贾俊楠, 安军等. 二甲双胍对肺结核合并2型糖尿病患者辅助治疗的横断面研究[J].中国热带医学, 2018, 18(6):609-613.
[11] STOCKBRIDGE EL, MILLER TL, CARLSON EK, et al.Private sector tuberculosis prevention in the US: Characteristics associated with interferon-gamma release assay or tuberculin skin testing[J]. PLoS One, 2018, 13(3):e0193432.
[12] KYU HH, MADDISON ER, HENRY NJ, et al.The global burden of tuberculosis: results from the Global Burden of Disease Study 2015[J]. Lancet Infect Dis, 2018,18(3):261-284.
[13] PRYOR R, CABREIRO F.Repurposing metformin: an old drug with new tricks in its binding pockets[J]. Biochem J, 2015, 471(3):307-322.
[14] SINGHAL A, JIE L, KUMAR P, et al. Metformin as adjunct antituberculosis therapy.[J]. Sci Transl Med, 2014, 6(263):263ra159.
[15] 陈妙姣, 张晶晶, 刘石平,等. 二甲双胍对RAW264.7鼠巨噬细胞极化及Notch1表达的影响[J].中华医学杂志, 2015, 95(16):1258-1261.
[16] LEE H, KIM J, AN J, et al.Downregulation of IL-18 Expression in the Gut by Metformin-induced Gut Microbiota Modulation[J]. Immune Netw, 2019, 19(4):e28.
[17] LIU X, REN S, GE C, et al.Sca1+Lin-CD117- Mouse Bone Marrow-Derived Mesenchymal Stem Cells Regulate Immature Dendritic Cell Maturation by Inhibiting TLR4-IRF8 Signaling Via the Notch-RBP-J Pathway[J]. Stem Cells Dev, 2018,27(8):556-565.
[18] XU H, ZHU J, SMITH S, et al.Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization[J]. Nat Immunol, 2012,13(7):642-650.
[19] 张红月. 老年2型糖尿病患者并发肺结核的危险因素[J]. 中国老年学杂志, 2017, 37(17):4258-4259.
[20] TONNEIJCK L, MUSKIET MH, SMITS MM,et al.Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment[J]. J Am Soc Nephrol, 2017, 28(4):1023-1039.
[21] KLIMONTOV VV, KORBUT AI.Normoal buminuric chronic kidney disease in diabetes[J]. Ter Arkh, 2018, 90(10):94-98.
[22] SHU CC, WEI YF, YEH YC, et al.The impact on incident tuberculosis by kidney function impairment status: analysis of severity relationship[J]. Respir Res, 2020, 21(1):51.
[23] NORRIS KC, SMOYER KE, ROLLAND C, et al.Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review[J]. BMC Nephrol, 2018, 19(1):36.
[24] GAO P, XU B, SONG P, et al.The Kidney Specific Protein myo-Inositol Oxygenase, a Potential Biomarker for Diabetic Nephropathy[J]. Kidney Blood Press Res, 2018, 43(6):1772-1785.
[25] ]JIN J, SHI Y, GONG J, et al. Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte[J]. Stem Cell Res Ther, 2019, 10(1):95.